drugset
Drugs / GX-03
last change Nov 2025 re-read 9 days ago

GX-03

Developed for
atopic eczema
Investigated by
Turn Therapeutics

Trials 1

today NCT07355075 · Ph 2/3
20262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2/3 NCT07355075 Jul 2025 → Jan 2027 expected atopic eczema Turn Therapeutics Recruiting No outcome recorded

News releases announcing trial results or a regulatory action · 2

DateIssuerRelease
2025-10-22 Turn Therapeutics Results Turn Therapeutics Provides Shareholder Update Highlighting Continued Execution Across Clinical and Strategic Milestones turntherapeutics.com ↗
A blinded, aggregate safety summary provided by the contract research organization indicated no safety or tolerability concerns across the 25% of participants who have completed the trial, representing over 1,000 total confirmed applications of study product
2024-08-05 Turn Therapeutics Results Atopic Dermatitis Drug Candidate Significantly Inhibits Key Cytokines in Expansion Study turntherapeutics.com ↗
GX-03 showed inhibition of key cytokines implicated in multiple dermatological conditions, including atopic dermatitis.

All press releases naming this drug 3 releases

DateIssuerRelease

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as GX-03 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07355075 ↗
Route Topical “topically applied GX-03” NCT07355075 ↗